Measurement Properties of the EQ-5D in Hematological Cancers: A Systematic Review
Author(s)
Aleksandra Dudzisz, MSc1, Dominik Golicki, Prof.2.
1Medical University of Warsaw, Warsaw, Poland, 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
1Medical University of Warsaw, Warsaw, Poland, 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
OBJECTIVES: The purpose of this systematic review is to consolidate the existing evidence on the measurement properties - validity, test-retest reliability, and responsiveness of the EQ-5D (EQ-5D-3L or EQ-5D-5L) in the context of their indexes and descriptive systems, and EQ VAS in the haematological cancer patient population.
METHODS: A comprehensive literature search was carried out utilizing the MEDLINE and EMBASE (up to January 2025). Full-text English articles focusing on original research concerning the measurement properties of the EQ-5D, including construct validity, test-retest reliability, or responsiveness, were included. Studies involving experimental versions of the EQ-5D were excluded. The quality assessment utilized the COSMIN Risk of Bias checklist, and data synthesis followed the COSMIN methodology.
RESULTS: A total of 15 studies from 30 countries, presenting 889 individual tests of the EQ-5D measurement properties were included. Sufficient construct validity for EQ-5D-5L index, EQ-5D-5L dimensions, EQ-5D-3L index, EQ-5D-3L dimensions, and EQ VAS was supported by high certainty. Evidence regarding test-retest reliability was limited to EQ-5D-5L index and EQ VAS, had moderate certainty, and indicated sufficient overall rating of measurement properties. Data for responsiveness was limited to EQ-5D-5L index and EQ-5D-3L index.
CONCLUSIONS: This review systematically compiles evidence on the measurement properties of the EQ-5D in the context of haematological cancers. The available evidence suggests that both EQ-5D-3L and EQ-5D-5L have sufficient convergent validity, and may be used to assess HRQoL in this patient population.
METHODS: A comprehensive literature search was carried out utilizing the MEDLINE and EMBASE (up to January 2025). Full-text English articles focusing on original research concerning the measurement properties of the EQ-5D, including construct validity, test-retest reliability, or responsiveness, were included. Studies involving experimental versions of the EQ-5D were excluded. The quality assessment utilized the COSMIN Risk of Bias checklist, and data synthesis followed the COSMIN methodology.
RESULTS: A total of 15 studies from 30 countries, presenting 889 individual tests of the EQ-5D measurement properties were included. Sufficient construct validity for EQ-5D-5L index, EQ-5D-5L dimensions, EQ-5D-3L index, EQ-5D-3L dimensions, and EQ VAS was supported by high certainty. Evidence regarding test-retest reliability was limited to EQ-5D-5L index and EQ VAS, had moderate certainty, and indicated sufficient overall rating of measurement properties. Data for responsiveness was limited to EQ-5D-5L index and EQ-5D-3L index.
CONCLUSIONS: This review systematically compiles evidence on the measurement properties of the EQ-5D in the context of haematological cancers. The available evidence suggests that both EQ-5D-3L and EQ-5D-5L have sufficient convergent validity, and may be used to assess HRQoL in this patient population.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
SA66
Topic
Methodological & Statistical Research, Patient-Centered Research, Study Approaches
Topic Subcategory
Literature Review & Synthesis
Disease
Oncology